Beam Therapeutics $180 million IPO
Davis Polk advised the joint book-running managers in connection with the $180 million initial public offering of common stock of Beam Therapeutics Inc. The common stock is listed on the…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Integra LifeSciences Holdings $575 million convertible senior notes offering
Davis Polk advised the joint book-running managers and representatives of the initial purchasers on a Rule 144A offering by Integra LifeSciences Holdings Corporation of $575 million…
Progyny $149.5 Million Initial Public Offering and Nasdaq Listing
Davis Polk advised the underwriters on the SEC-registered initial public offering by Progyny, Inc. of 11,500,000 common shares, consisting of 6,700,000 shares sold by Progyny and 4,800,000…
Innate Pharma $79 Million U.S. Initial Public Offering of ADS on Nasdaq and Concurrent Private Placement
Davis Polk advised the underwriters in connection with an initial public offering of 8,047,227 American Depositary Shares of Innate Pharma S.A. and a concurrent private placement of 4,452…
BioNTech SE Initial Public Offering on Nasdaq
Davis Polk advised the underwriters in connection with the $150 million initial public offering of 10,000,000 American Depositary Shares of BioNTech SE. In addition, the underwriters have…
Beazer Homes USA, Inc. $350 Million Notes Offering and Concurrent Cash Tender Offer and Consent Solicitation
Davis Polk advised the joint book-running managers in connection with an offering by Beazer Homes USA, Inc. of $350 million aggregate principal amount of its 7.250% notes due 2029.
Davis…
PTC Therapeutics, Inc. Concurrent $100 Million Common Stock Offering and $287.5 Million Convertible Senior Notes Offering
Davis Polk advised the underwriter in connection with the SEC-registered offering by PTC Therapeutics, Inc. of 2,475,248 shares of its common stock and the initial purchaser in a concurrent…
Davis Polk Advises Murphy USA on Its $500 Million Notes Offering and Tender Offer
Davis Polk advised Murphy USA Inc. in connection with an SEC-registered offering of $500 million aggregate principal amount of 4.750% senior notes due 2029 and a tender offer for any and…
Insulet Corporation Convertible Senior Notes Offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Insulet Corporation of $800 million principal amount of 0.375% convertible senior notes due 2026,…
PTC Therapeutics, Inc. $125 Million SEC-Registered At-The-Market Offering
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by PTC Therapeutics, Inc. of its shares of common stock for up to an aggregate amount of $125…